PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) Revenue
Annual & quarterly revenue history · segment & region breakdown
PTCT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsPTC Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.83B, an increase of 114.51% year-over-year from $1.73B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1.73B | +$0.92B | +114.51% |
| 2024-12-31 | $0.81B | -$0.13B | -13.97% |
| 2023-12-31 | $0.94B | +$0.24B | +34.20% |
| 2022-12-31 | $0.70B | +$0.16B | +29.75% |
| 2021-12-31 | $0.54B | +$0.16B | +41.45% |
| 2020-12-31 | $0.38B | +$0.07B | +24.04% |
| 2019-12-31 | $0.31B | +$0.04B | +15.96% |
| 2018-12-31 | $0.26B | +$0.07B | +36.19% |
| 2017-12-31 | $0.19B | +$0.11B | +135.04% |
| 2016-12-31 | $0.08B | +$0.05B | +124.95% |
Compare revenue vs peers
BiotechnologyCompare PTCT revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income PTC Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
PTC Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from PTC Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PTCT revenue · 4 questionsPTCT's trailing twelve-month (TTM) revenue is $0.83B. That is an increase of 114.51% year-over-year from $1.73B in FY2025.
▸ Source: FMP · PTC Therapeutics, Inc. SEC filings · GAAP · PTC Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026